Last updated: 2026-09-08 09:45:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Indivior Pharmaceuticals, Inc. (INDV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $35.01, with a market capitalization of $4.12B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22.22 to $42.81. This page covers its latest market performance, valuation, price trends and company information.
$4.12B | |
$35.10 | |
$42.81 | |
$7.33 | |
-- | |
412.00 | |
2.04M | |
-- | |
$42.81 | |
$22.22 | |
-- | |
-- |
Indivior Pharmaceuticals, Inc. (INDV) is trading at $34.71 in pre-market trading as of 2026-09-08 09:36:00, -- from the previous close of $0.00
Pre-market trading shows how investors are pricing INDV before the regular session opens. The current pre-market price is -- the previous close, indicating positive early trading sentiment.
Over the past seven days, Indivior Pharmaceuticals, Inc. (INDV) moved from $35.30 to $35.01, representing a decline of 0.81% ($0.29).
The stock traded between $34.33 and $35.95 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 2.06 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 62.1%
INDV is currently trading at $35.01, placing it 62.1% of the way from its 52-week low of $22.22 to its 52-week high of $42.81. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 838 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Indivior Pharmaceuticals, Inc. (INDV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.